Home > Protocol Summaries: Compounds > GSK2189242A Protocol Summaries: GSK2189242A GSKStudy ID Phase Title Status 111651 phase 1 A study to evaluate GSK Biologicals’ candidate formulations of pneumococcal vaccines (GSK2189242A) in young adults. Completed 112993 phase 2 A study to evaluate safety & immunogenicity of a booster dose of two formulations of GSK Biologicals’ pneumococcal candidate vaccine in healthy young adults Completed 113171 phase 2 Safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen in children aged 12-23 months at the time of first vaccination. Completed 113994 phase 2 Safety, reactogenicity & immunogenicity of GSK Biologicals’ pneumococcal vaccine 2189242A when co-administered with DTPa-HBV-IPV/Hib vaccine in healthy infants Completed
